Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

(2021) Max Jan et al.   Nature Reviews Clinical Oncology

Heart Failure With Targeted Cancer Therapies

(2021) Virginia S. Hahn et al.   CIRCULATION RESEARCH

Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents

(2020) Robert F. Cornell et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis

(2020) Avash Das et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Management of cardiovascular risk in patients with multiple myeloma

(2019) Chris Plummer et al.   Blood Cancer Journal

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

(2019) Joseph Mikhael et al.   JOURNAL OF CLINICAL ONCOLOGY

Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors

(2019) Bhaskar Roy et al.   NEUROLOGY

Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials

(2019) Somedeb Ball et al.   Clinical Lymphoma Myeloma & Leukemia

Cellular quality control by the ubiquitin-proteasome system and autophagy

(2019) Christian Pohl et al.   SCIENCE

Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence

(2018) Mara Gavazzoni et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

(2018) Heinz Ludwig et al.   LEUKEMIA

Carfilzomib-Associated Cardiovascular Adverse Events

(2018) Adam J. Waxman et al.   JAMA Oncology

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

(2018) Sara Bringhen et al.   HAEMATOLOGICA

Molecular mechanisms of Carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of Metformin

(2018) Panagiotis Efentakis et al.   BLOOD

Comparison of treatment options for depression in heart failure: A network meta-analysis

(2018) Avash Das et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

(2017) Young Kwang Chae et al.   MOLECULAR CANCER THERAPEUTICS

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies

(2017) Weijuan Li et al.   JAMA Oncology

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

(2015) E. Terpos et al.   HAEMATOLOGICA

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

(2015) E. Terpos et al.   HAEMATOLOGICA

Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies

(2014) Virginia Shalkey Hahn et al.   Journal of the American Heart Association

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH